Hochschulschrift
An Analysis of Genetic Alterations of the Epidermal Growth Factor Receptor and the Tyrosine Kinase 2 in Human Cancer Cell Lines
- Weitere Titel
-
Biochemische und funktionelle Charakterisierung genetischer Veränderungen von EGFR und Tyk2 in humanen Krebszelllinien
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
München, Technische Universität München, Diss., 2012
- Klassifikation
-
Medizin, Gesundheit
- Ereignis
-
Veröffentlichung
- (wo)
-
München
- (wer)
-
Universitätsbibliothek der TU München
- (wann)
-
2012
- Urheber
-
Tay, Liang-Seah
- Beteiligte Personen und Organisationen
- URN
-
urn:nbn:de:bvb:91-diss-20120327-1071113-1-0
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 15.08.2025, 05:20 UTC
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Objekttyp
- Hochschulschrift
Beteiligte
- Tay, Liang-Seah
- Budisa, Nediljko
- Groll, Michael
- Ullrich, Axel
- Universitätsbibliothek der TU München
Entstanden
- 2012
Ähnliche Objekte (12)
An analysis of genetic alterations of the epidermal growth factor receptor and the tyrosine kinase 2 in human cancer cell lines
Progress toward resistance mechanism to epidermal growth factor receptor tyrosine kinase inhibitor
Evaluation of Patients with Lung Cancer Treated with Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor
Redox-mediated regulation of the tyrosine kinase Zap70
Biased activation of the receptor tyrosine kinase HER2
Biased activation of the receptor tyrosine kinase HER2
Biased activation of the receptor tyrosine kinase HER2
Biased activation of the receptor tyrosine kinase HER2
Brk tyrosine kinase signaling in the gastrointestinal tract
Editorial: Targeting bruton tyrosine kinase
Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types
Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer: results and open issues
An analysis of genetic alterations of the epidermal growth factor receptor and the tyrosine kinase 2 in human cancer cell lines
Progress toward resistance mechanism to epidermal growth factor receptor tyrosine kinase inhibitor
Evaluation of Patients with Lung Cancer Treated with Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor
Redox-mediated regulation of the tyrosine kinase Zap70
Biased activation of the receptor tyrosine kinase HER2
Biased activation of the receptor tyrosine kinase HER2
Biased activation of the receptor tyrosine kinase HER2
Biased activation of the receptor tyrosine kinase HER2
Brk tyrosine kinase signaling in the gastrointestinal tract
Editorial: Targeting bruton tyrosine kinase
Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types
Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer: results and open issues
An analysis of genetic alterations of the epidermal growth factor receptor and the tyrosine kinase 2 in human cancer cell lines
Progress toward resistance mechanism to epidermal growth factor receptor tyrosine kinase inhibitor
Evaluation of Patients with Lung Cancer Treated with Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor
Redox-mediated regulation of the tyrosine kinase Zap70
Biased activation of the receptor tyrosine kinase HER2
Biased activation of the receptor tyrosine kinase HER2
Biased activation of the receptor tyrosine kinase HER2
Biased activation of the receptor tyrosine kinase HER2
Brk tyrosine kinase signaling in the gastrointestinal tract
Editorial: Targeting bruton tyrosine kinase
Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types